Skip to content

Effect of Acupuncture in Treatment of Diabetes

Evaluating Therapeutic Effects of Acupuncture on Blood Glucose Level among Patients with Type 2 Diabetes Mellitus

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20180914041035N1
Enrollment
80
Registered
2018-10-11
Start date
2018-08-29
Completion date
Unknown
Last updated
2018-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus. Type 2 diabetes mellitus

Interventions

Intervention 1: Intervention group: Acupuncture. According to textbooks, literature review and the clinical experience of the principal researcher, fifteen body acupoints were selected including Waigu

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients with diagnosis of type 2 diabetes mellitus according to American diabetes association diagnostic criteria, who are under treatment with metformin to control their blood glucose (500-1500 mg/day) Signed the written informed consent Fasting plasma glucose between 140-250 mg/dL Aged 35-65 years

Exclusion criteria

Exclusion criteria: Cardiovascular diseases (history of heart failure, New York heart association function class III-IV, myocardial infarction, acute coronary syndromes, pacemaker implantation, coronary revascularization and stroke) Renal impairment (urinary albumin excretion = 30 mg/day, estimated glomerular filtration rate < 60 mL/min/1.73 m2) Hepatic impairment (abnormal serum aminotransferases, liver cirrhosis) Cognitive impairment, inability of cooperation Fasting plasma glucose = 250 mg/dL or hemoglobin A1C = 9 Pregnancy or breastfeeding Diabetic patients that use other medications than metformin to control their blood glucose such as insulin Evidence of lower limb infection, wound and ischemia (ecchymosis, bright skin, ABI<0.9)

Design outcomes

Primary

MeasureTime frame
Fasting plasma glucose. Timepoint: Evaluating Fasting plasma glucose at baseline (before the treatment), and 1, 2, 4, 6 and 12 weeks after the initiation of treatment. Method of measurement: Laboratory kit.

Secondary

MeasureTime frame
Hemoglobin A1c. Timepoint: Evaluating HbA1c at baseline (before the treatment) and 12 weeks after the initiation of treatment. Method of measurement: Laboratory kit.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmir Hooman Kazemi

Tehran University of Medical Sciences

hooman_k@tums.ac.ir+98 21 2298 8548

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026